Aim: Therapeutic efficacy of pulmonary diseases is often limited and drug delivery systems offer new solutions to clinical problems. Solid lipid microparticles (SLMs) are suggested as systems for the delivery of therapeutics to the lung as, because of their size, they are able to deposit into secondary bronchi. Materials & methods: Here, we describe two novel different SLMs using chitosan and alginate such as mucoadhesive polymers and we also studied their biocompatibility and their effectiveness compared with the free drug in controlling senescence and inflammatory processes in cigarette smoke extracts. Results: Data reported show that fluticasone propionate (FP)-loaded SLMs are more effective than FP alone in controlling oxidative stress....
Traditional formulations for pulmonary drug delivery mainly focused on two approaches: (i) Dissolvin...
Toward engineering approaches that are designed to optimize the particle size, morphology, and mucoa...
Although dated back of some years, the opportunity to selectively target a drug to lungs remains a f...
AIM: Therapeutic efficacy of pulmonary diseases is often limited and drug delivery systems offer new...
Chronic obstructive pulmonary disease (COPD) is one of the main health problems worldwide. It is cha...
Mucoadhesive based pulmonary drug delivery is an advanced novel intervention against several pulmona...
Inhaling drugs, on the other hand, is limited mainly by the natural mechanisms of the respiratory sy...
The controlled release of drugs for pulmonary, delivery is a research field which has been so far ra...
Oxidative stress is intensely involved in enhancing the severity of various chronic respiratory dise...
Diseases in the respiratory tract rank among the leading causes of death in the world, and thus nove...
Aim: Current inhaled treatments are not adequate to treat all lung diseases. In this study, a promis...
The 21st century has seen a paradigm shift to inhaled therapy, for both systemic and local drug deli...
Cystic fibrosis (CF) is a complex, potentially life-threatening disease that is most effectively tre...
Drug delivery to the lungs by inhalation offers a targeted drug therapy for respiratory diseases. Ho...
The Pulmonary route has been traditionally used to treat diseases of the respiratory tract. However,...
Traditional formulations for pulmonary drug delivery mainly focused on two approaches: (i) Dissolvin...
Toward engineering approaches that are designed to optimize the particle size, morphology, and mucoa...
Although dated back of some years, the opportunity to selectively target a drug to lungs remains a f...
AIM: Therapeutic efficacy of pulmonary diseases is often limited and drug delivery systems offer new...
Chronic obstructive pulmonary disease (COPD) is one of the main health problems worldwide. It is cha...
Mucoadhesive based pulmonary drug delivery is an advanced novel intervention against several pulmona...
Inhaling drugs, on the other hand, is limited mainly by the natural mechanisms of the respiratory sy...
The controlled release of drugs for pulmonary, delivery is a research field which has been so far ra...
Oxidative stress is intensely involved in enhancing the severity of various chronic respiratory dise...
Diseases in the respiratory tract rank among the leading causes of death in the world, and thus nove...
Aim: Current inhaled treatments are not adequate to treat all lung diseases. In this study, a promis...
The 21st century has seen a paradigm shift to inhaled therapy, for both systemic and local drug deli...
Cystic fibrosis (CF) is a complex, potentially life-threatening disease that is most effectively tre...
Drug delivery to the lungs by inhalation offers a targeted drug therapy for respiratory diseases. Ho...
The Pulmonary route has been traditionally used to treat diseases of the respiratory tract. However,...
Traditional formulations for pulmonary drug delivery mainly focused on two approaches: (i) Dissolvin...
Toward engineering approaches that are designed to optimize the particle size, morphology, and mucoa...
Although dated back of some years, the opportunity to selectively target a drug to lungs remains a f...